Skip to content
Logo
  • Home
  • FeNO
    • What is FeNO?
    • FeNO in asthma
    • Benefits of FeNO use
    • Measuring FeNO with the NObreath®
  • NObreath®
    • What is the NObreath®?
    • Already own a NObreath®
    • How to use the NObreath®
    • Consumables
    • Where to buy?
    • Literature
  • Forum
  • News
  • Medical Advisory Board
  • Software
  • Support
    • Educational Portal
    • FAQs
    • Literature
    • How to videos
    • Coronavirus and FeNO testing
  • Contact
  • United States
    • English
    • United States
Sep 23

World Lung Day 2022

World Lung Day is an annual occurrence on the 25th September, which aims to promote better lung health. Poor lung health can lead to many conditions, including asthma, a chronic condition of the lungs, causing difficulty in breathing, that affects over 12% of the UK population1. But thanks to technologies like Fractional exhaled Nitric Oxide (FeNO) monitoring with the NObreath®, Healthcare Professionals can offer patients a quick, easy, and non-invasive, method which helps in the diagnosis and monitoring of asthma.

Airway inflammation is a central process in asthma and other lung diseases2. Nitric Oxide (NO) is naturally produced by your body to help combat inflammation and when your airway is inflamed, NO is produced in the lungs and exhaled on the breath3. NO is exhaled in very miniscule particles known as Fractional exhaled Nitric Oxide (FeNO) and is measured in parts per billion (ppb).

A FeNO test can help to differentiate between allergic (eosinophilic) and non-allergic asthma4, identify patients who do/do not require ongoing treatment5, and help predict and prevent asthma attacks6.

To learn more about how FeNO testing can improve asthma care and more, please watch The Role of FeNO in Primary Care Respiratory Diagnostics.

 

References

  1. Asthma statistics | British Lung Foundation [Internet]. Statistics.blf.org.uk. 2022 [cited 14 September 2022]. Available from: https://statistics.blf.org.uk/asthma
  2. Shelhamer JH, Levine SJ, Wu T, Jacoby DB, Kaliner MA, Rennard SI. NIH conference: airway inflammation. Ann Intern Med 1995;123:288-304.
  3. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005; American Journal of Respiratory and Critical Care Medicine; vol. 171: 912-930;2005
  4. Coumou HBel E. Improving the diagnosis of eosinophilic asthma [Internet]. Taylor and Francis online. 2017 [cited 23 September 2022]. Available from: http://www.tandfonline.com/doi/full/10.1080/17476348.2017.1236688
  5. D R Taylor, MW Pinenburg, A D Smith and J C D Jongste. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006;61:817-827.
  6. Harkins M. Exhaled Nitric Oxide Predicts Asthma Exacerbation [Internet]. Taylor & Francis. 2017 [cited 23 September 2022]. Available from: http://www.tandfonline.com/doi/abs/10.1081/JAS-120033990

Leave a reply Cancel reply

Your email address will not be published. Required fields are marked *

Contact Details

Bedfont® Scientific Ltd
Station Road, Harrietsham, Maidstone
Kent, ME17 1JA, England

Tel: +44(0)1622 851122
Email: ask@bedfont.com

Products

NObreath®

Smokerlyzer®

Gastrolyzer®

ToxCO®

Medi-Gas Check

Accreditations

ISO 13485:2016

Bedfont EC REP - Emergo

Useful Links

What is FeNO?

FeNOchart™

What is the NObreath®?

Resources

FAQs

Contact Us


References



White Bedfont text logo

© 1976-2025 Bedfont® Scientific Ltd., all rights reserved | Incorporated in England and Wales under registered number: 1289798

Legal Stuff | Privacy Notice | Help Centre